Item 1(a).
|
Name of Issuer:
|
Amicus Therapeutics, Inc. (the Issuer)
Item 1(b).
|
Address of Issuers Principal Executive Offices:
|
1 Cedar Brook Drive, Cranbury, NJ 08512
Item 2(a).
|
Names of Persons Filing:
|
The names of the persons filing this report (collectively, the Reporting Persons) are:
Perceptive Advisors LLC (Perceptive Advisors)
Joseph Edelman (Mr. Edelman)
Perceptive Life Sciences Master Fund, Ltd. (the Master Fund)
Item 2(b).
|
Address of Principal Business Office or, if None, Residence:
|
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New
York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d).
|
Title of Class of Securities:
|
Common Stock, par value $0.01 per share (Common Stock)
03152W 10 9
Item 3.
|
If this statement is filed pursuant to §§
240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this
Schedule 13G. The ownership percentages reported are based on 254,809,971 outstanding shares of Common Stock, as reported in the Issuers Form 8-K filed on November 12, 2019.
The Master Fund directly holds 25,132,364 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and
may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.